Oruka Therapeutics, Inc. research snapshot
ORKA AI stock analysis reads Oruka Therapeutics as a high-conviction clinical-stage biotech pursuing best-in-class monoclonal antibodies for psoriasis and related inflammatory conditions. At the July 12, 2026 data cutoff, ORKA traded around $86.79 with a verified market capitalization near $5.23 billion. The ORKA AI stock forecast uses scenario ranges instead of a fixed price prediction because clinical trial results, regulatory decisions, competitive dynamics, financing needs, and partnership outcomes can change the investment case rapidly.
Current price
$86.79 close on July 10, 2026; 52-week range $12.84 to $97.78
Market cap
$5.23 billion verified market cap
AI score
48 / 100
Rating
High-upside clinical-stage biotech with phase 2 psoriasis data, substantial cash runway, analyst support, but no revenue, GAAP losses, pipeline binary risk, and extreme volatility
Trend status
Well above the 50-day and 200-day moving averages after a 516% one-year run, but still near the upper end of the 52-week range with elevated volatility
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Oruka has no approved products or revenue. The business is entirely preclinical and clinical-stage, with value dependent on ORKA-001 (anti-IL-23 p19) and ORKA-002 (anti-IL-17A/F) phase 2 data in psoriasis. | Low |
| Moat | No proven moat yet. If ORKA-001 or ORKA-002 achieve best-in-class efficacy and dosing convenience (1-2 doses per year), they could carve a durable position against Skyrizi, Tremfya, Bimzelx, and Cosentyx. Until then, the moat is hypothetical. | Low |
| Management | The team comprises seasoned biopharma professionals with prior experience in dermatology and immunology drug development. Key-person risk is elevated given the small 68-employee organization. Insider selling of 105,000 shares worth $6.2 million was reported. | Low |
| Financial trend | No revenue, negative GAAP net income of about -$94.19 million TTM, negative levered free cash flow of about -$56.13 million TTM, and cash of $388.83 million. The cash runway supports operations into clinical data readouts, but future dilution is likely. | Medium |
| Valuation | At $86.79, ORKA trades at 10.82x book value with no P/E (negative earnings) and no P/S (no revenue). The $5.23B market cap vs $388.83M cash implies the market is assigning billions in pipeline value. Analyst targets average $144.67. | Low |
| Technical trend | The stock is in a strong uptrend from its 52-week low of $12.84, gaining 516% over the past year. It recently approached $97.78 before pulling back to $86.79. Volume is active with 1.8 million shares average daily turnover. | Medium |
| Risk level | Extreme. Risks include phase 2 trial failure for both lead assets, regulatory rejection, competitive pressure from approved IL-23 and IL-17 inhibitors, financing and dilution risk, insider selling, and the binary nature of clinical-stage biotech investing. | High |
| AI confidence | Descriptive confidence is medium-high for current financial position and market data. Return confidence is very low because clinical-stage biotech outcomes depend on binary scientific events that no AI model can predict with reliability. | Low return confidence |
| Investment certainty | Very low. ORKA is a speculative biotech bet suited only for investors who understand that phase 2 data can move the stock 50-100% in either direction and who can tolerate a total loss of capital. | Very low |
ORKA AI stock forecast
The ORKA AI stock forecast is scenario-based because Oruka has no revenue and its entire valuation depends on clinical trial outcomes for ORKA-001 and ORKA-002. Using an $86.79 price reference and analyst targets ranging from $102 to $200, the mechanical outcomes over a 12-18 month framework are about $145 to $200 in a bullish case, $80 to $100 in a neutral case, and $15 to $30 in a bearish case.
$145 to $200
More likely if ORKA-001 or ORKA-002 report positive phase 2 data showing best-in-class efficacy (high PASI 90/100 rates) and favorable dosing, leading to analyst upgrades, partnership interest, and a valuation re-rating toward or above the current average analyst target of $144.67.
$80 to $100
More likely if phase 2 data are competitive but not clearly best-in-class, the stock holds its current valuation while the market waits for phase 3 data, cash burn continues, and no partnership or financing catalyst emerges.
$15 to $30
More likely if phase 2 data disappoint on efficacy or safety, regulatory concerns emerge, competition intensifies, or the company needs dilutive financing at a lower stock price. A return toward the 52-week low of $12.84 is possible in a worst case.
ORKA AI technical analysis
ORKA AI technical analysis reflects an aggressive uptrend with high volatility as of the July 12, 2026 data cutoff. Yahoo Finance showed a July 10 close of $86.79, a 52-week range of $12.84 to $97.78, and average daily volume near 1.82 million shares. The stock has gained 186% year-to-date and 517% over the past year, indicating strong momentum but also elevated risk of profit-taking.
| Level | Value | Why it matters |
|---|---|---|
| Current price reference | $86.79 close on July 10, 2026 | The stock pulled back from its recent high near $97.78, suggesting short-term consolidation after a strong run. |
| Immediate support | $80 to $85 | This range represents the recent pullback zone and prior resistance-turned-support area from June 2026 trading. |
| Key support | $60 to $70 | This zone served as resistance in May 2026 before breaking higher. A hold above this area would maintain the uptrend structure. |
| Major support | $35 to $45 | This range represents the consolidation area from early 2026 before the stock broke out above $50. |
| Near resistance | $94 to $98 | The recent high of $97.78 is the immediate resistance. A break above this level with volume would signal trend continuation. |
| Upper resistance | $130 to $145 | UBS raised its price target to $130 and the average analyst target is $144.67. These levels represent potential upside targets if catalysts are positive. |
| Moving averages | All key MAs likely well below current price | After a 517% one-year gain, the 50-day and 200-day moving averages are likely far below the current price, offering limited technical reference. |
| Momentum | Strongly positive but extended | The 186% YTD gain and 517% 1-year gain reflect extreme momentum. RSI is likely elevated and the stock may be overbought on longer timeframes. |
| Volume | Average volume near 1.82 million shares | Volume tends to spike on news events (trial data, analyst actions). Watch for volume confirmation on any breakout above $98. |
| Invalidation | Close below $60, then below $35 | A sustained move below $60 would suggest the uptrend is weakening. A break below the $35 to $45 zone would signal a potential trend reversal. |
ORKA AI trading strategy
The ORKA AI trading strategy below is a rules-based research framework, not personal advice. It connects price levels with clinical trial timelines, cash position, analyst ratings, pipeline catalysts, and insider trading activity.
Watch for ORKA to approach phase 2 data readout dates with increasing volume and bullish positioning. A breakout above $98 with strong volume ahead of data could signal institutional accumulation.
Position sizing must account for the binary nature of clinical data. A 20-30% position reduction before major data readouts is a common risk management approach for clinical-stage biotech. Do not add to positions after a rapid run-up without a fresh catalyst.
If ORKA pulls back to the $60 to $70 support zone without a negative catalyst, compare the lower price with cash position, analyst targets, pipeline timeline, and insider trading activity.
Do not buy every dip in a clinical-stage biotech. A pullback before data may reflect fair reassessment rather than an opportunity. Check whether insider selling has accelerated before adding.
Track phase 2 enrollment completion, data readout timelines, analyst ratings and price target changes, cash burn rate vs runway, partnership or licensing news, insider buying/selling patterns, and competitor data in IL-23 and IL-17 space.
The maximum position size in a single clinical-stage biotech should reflect the understanding that negative data can make the stock worthless. Diversification across multiple pipeline-stage companies is essential.
Investment research summary
Customers (patients and physicians) would pay for Oruka monoclonal antibodies if they deliver higher skin clearance rates with fewer injections per year than currently approved IL-23 and IL-17 inhibitors. The economic engine is pipeline-driven, with no current product revenue.
The potential moat comes from best-in-class efficacy data, convenient dosing (1-2 doses/year), intellectual property, and manufacturing know-how. It is entirely unproven until phase 2 data are published. The approved psoriasis market is crowded with Skyrizi, Tremfya, Bimzelx, Cosentyx, and others.
The thesis fails if ORKA-001 and ORKA-002 show efficacy or safety that is merely competitive rather than clearly superior, if the cash runway runs out before value-inflection data, if a competitor advances a better molecule, or if the insider selling pattern signals lack of confidence from those closest to the science.
The leadership team brings relevant biopharma experience in dermatology and immunology. The small team size (68 employees) means key-person risk is real. Insider selling activity is a factor to monitor for confidence signals.
Psoriasis and inflammatory disease represent large and growing markets with significant unmet need for more convenient, higher-efficacy treatments. The IL-23 and IL-17 classes are well-validated, and the shift toward biologic therapies continues. The counterweight is a crowded and competitive market.
The current $5.23 billion market cap implies the market assigns billions in value to a pipeline that has not yet produced phase 2 data. Margin of safety is extremely low until clinical proof-of-concept is established. The analyst target of $144.67 represents potential upside only if phase 2 data are positive.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $86.79 close on July 10, 2026 | Yahoo Finance | July 12, 2026 |
| Market capitalization | $5.23 billion as of July 10, 2026 | Yahoo Finance market cap | July 12, 2026 |
| Enterprise value | $4.85 billion | Yahoo Finance key statistics | July 12, 2026 |
| 52-week range | $12.84 to $97.78 | Yahoo Finance | July 12, 2026 |
| Cash position | $388.83 million total cash (mrq) | Yahoo Finance key statistics | July 12, 2026 |
| TTM net income | -$94.19 million | Yahoo Finance key statistics | July 12, 2026 |
| TTM EPS | -$1.93 | Yahoo Finance | July 12, 2026 |
| Price/book ratio | 10.82 | Yahoo Finance key statistics | July 12, 2026 |
| Analyst price target | Average $144.67 (range $102 to $200) | Yahoo Finance and UBS | July 12, 2026 |
| Volume | 499,644 (latest); average 1,815,469 | Yahoo Finance | July 12, 2026 |
This ORKA AI stock analysis is an informational research tool only. It is not investment advice, a solicitation, or a personalized recommendation. Forecast scenarios are based on available public data as of the stated cutoff date and can be wrong if clinical trial results, regulatory decisions, competitive dynamics, financing needs, analyst estimates, or market conditions change. Clinical-stage biotech investments carry a risk of total capital loss.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
